Status: Recruiting
Exploration of Circular RNA in B-cell Hematologic Malignancies
This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Aug 19, 2026Locations: 2
Eligibility criteria
Age ≥ 18 years, any gender. [+14]
Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1... [+19]